Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Payables: 2020-2025

Historic Payables for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $50.3 million.

  • GeneDx Holdings' Payables fell 10.78% to $50.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.4 million, marking a year-over-year decrease of 3.27%. This contributed to the annual value of $31.0 million for FY2024, which is 17.28% down from last year.
  • According to the latest figures from Q3 2025, GeneDx Holdings' Payables is $50.3 million, which was up 2.22% from $49.2 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year Payables high stood at $115.9 million for Q2 2022, and its period low was $31.0 million during Q4 2024.
  • Over the past 3 years, GeneDx Holdings' median Payables value was $49.2 million (recorded in 2025), while the average stood at $46.7 million.
  • As far as peak fluctuations go, GeneDx Holdings' Payables spiked by 223,815.85% in 2021, and later plummeted by 55.87% in 2023.
  • Quarterly analysis of 5 years shows GeneDx Holdings' Payables stood at $44.7 million in 2021, then spiked by 89.91% to $84.9 million in 2022, then slumped by 55.87% to $37.5 million in 2023, then decreased by 17.28% to $31.0 million in 2024, then declined by 10.78% to $50.3 million in 2025.
  • Its Payables was $50.3 million in Q3 2025, compared to $49.2 million in Q2 2025 and $41.9 million in Q1 2025.